Drug Information

Drug (ID: DG01883) and It's Reported Resistant Information

• Name: GSK3052230
• Synonyms: GSK3052230
• Indication:
  In total 1 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Investigative; [1]
• Target: Fibroblast growth factor (FGF); NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Endometrial cancer [ICD-11: 2C76]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Fibroblast growth factor receptor 2 (FGFR2) [1]

• Molecule Alteration: Missense mutation; p.S252W (c.755C>G)
• Sensitive Disease: Endometrial adenocarcinoma [ICD-11: 2C76.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Lung; N.A.
• Experiment for Molecule Alteration: QuantiGene Plex DNA assay
• Mechanism Description: The missense mutation p.S252W (c.755C>G) in gene FGFR2 cause the sensitivity of GSK3052230 by aberration of the drug's therapeutic target

References

• Ref 1: Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancerSci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.